WFRF:(Gion M)
Sökning: WFRF:(Gion M) > Design of Tumor Bio...
LIBRIS Formathandbok (Information om MARC21)
| Fältnamn | Indikatorer | Metadata |
|---|---|---|
| 000 | 02818naa a2200445 4500 | |
| 001 | oai:DiVA.org:uu-194755 | |
| 003 | SwePub | |
| 008 | 130219s2013 | |||||||||||000 ||eng| | |
| 024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-1947552 URI |
| 024 | 7 | a https://doi.org/10.1373/clinchem.2011.1807782 DOI |
| 040 | a (SwePub)uu | |
| 041 | a engb eng | |
| 042 | 9 SwePub | |
| 072 | 7 | a ref2 swepub-contenttype |
| 072 | 7 | a art2 swepub-publicationtype |
| 100 | 1 | a Soletormos, Gyorgy4 aut |
| 245 | 1 0 | a Design of Tumor Biomarker-Monitoring Trials :b A Proposal by the European Group on Tumor Markers |
| 264 | c 2013-01-01 | |
| 264 | 1 | b Oxford University Press (OUP),c 2013 |
| 338 | a print2 rdacarrier | |
| 520 | a A major application of tumor biomarkers is in serial monitoring of cancer patients, but there are no published guidelines on how to evaluate biomarkers for this purpose. The European Group on Tumor Markers has convened a multidisciplinary panel of scientists to develop guidance on the design of such monitoring trials. The panel proposes a 4-phase model for biomarker-monitoring trials analogous to that in use for the investigation of new drugs. In phase I, biomarker kinetics and correlation with tumor burden are assessed. Phase II evaluates the ability of the biomarker to identify, exclude, and/or predict a change in disease status. In phase III, the effectiveness of tumor biomarker guided intervention is assessed by measuring patient outcome in randomized trials. Phase IV consists of an audit of the long-term effects after biomarker monitoring has been included into standard patient care. Systematic well-designed evaluations of biomarkers for monitoring may provide a stronger evidence base that might enable their earlier use in evaluating responses to cancer therapy. | |
| 700 | 1 | a Duffy, Michael J.4 aut |
| 700 | 1 | a Hayes, Daniel F.4 aut |
| 700 | 1 | a Sturgeon, Catharine M.4 aut |
| 700 | 1 | a Barak, Vivian4 aut |
| 700 | 1 | a Bossuyt, Patrick M.4 aut |
| 700 | 1 | a Diamandis, Eleftherios P.4 aut |
| 700 | 1 | a Gion, Massimo4 aut |
| 700 | 1 | a Hyltoft-Petersen, Per4 aut |
| 700 | 1 | a Lamerz, Rolf M.4 aut |
| 700 | 1 | a Nielsen, Dorte L.4 aut |
| 700 | 1 | a Sibley, Paul4 aut |
| 700 | 1 | a Tholander, Bengtu Uppsala universitet,Enheten för onkologi4 aut0 (Swepub:uu)betho227 |
| 700 | 1 | a Tuxen, Malgorzata K.4 aut |
| 700 | 1 | a Bonfrer, Johannes M. G.4 aut |
| 710 | 2 | a Uppsala universitetb Enheten för onkologi4 org |
| 773 | 0 | t Clinical Chemistryd : Oxford University Press (OUP)g 59:1, s. 52-59q 59:1<52-59x 0009-9147x 1530-8561 |
| 856 | 4 | u http://clinchem.aaccjnls.org/content/clinchem/59/1/52.full.pdf |
| 856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-194755 |
| 856 | 4 8 | u https://doi.org/10.1373/clinchem.2011.180778 |
Hitta mer i SwePub
- Av författaren/redakt...
- Soletormos, Gyor ...
- Duffy, Michael J ...
- Hayes, Daniel F.
- Sturgeon, Cathar ...
- Barak, Vivian
- Bossuyt, Patrick ...
- visa fler...
- Diamandis, Eleft ...
- Gion, Massimo
- Hyltoft-Petersen ...
- Lamerz, Rolf M.
- Nielsen, Dorte L ...
- Sibley, Paul
- Tholander, Bengt
- Tuxen, Malgorzat ...
- Bonfrer, Johanne ...
- visa färre...
- Artiklar i publikationen
- Clinical Chemist ...
- Av lärosätet
- Uppsala universitet
Sök utanför SwePub
- Sök vidare i:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - Nationella bibliotekssystem
- LIBRIS.kb.se
